Use of diverse testing modalities to facilitate access to HIV testing for New Zealand key populations

New Zealand AIDS Foundation

Anderson A, Beaumont J, Ludlam A, Rich J

Background/Purpose:

Reducing rates of undiagnosed HIV in New Zealand is a core strategic goal for the New Zealand AIDS Foundation (NZAF). Ensuring NZAF provides testing services to gay, bisexual and other men who have sex with men (GBM) that are equitable, accessible and acceptable is essential.

The NZAF delivers a range of rapid testing service types both within and beyond clinic settings, to meet the diverse needs of priority populations. These testing opportunities include point-of-care rapid testing at community health centres (booked appointments or walk-in), outreach at sex-on-site (SOS) venues, and HIV self-testing.

The aim of this project was to assess whether providing additional testing modalities effectively targets more diverse client sub-populations.

Approach: We analysed NZAF HIV testing client data from the period between May 2018 and April 2019. It includes ethnicity, reported condom use, and previous testing. We compared client characteristics associated with different testing modalities.

Outcomes/Impact:

	NZAF centres – booked. (n=2206)	NZAF centres - walk-in (n=611)	Self-test (n=1261)	Sex-on-site venue outreach (n=124)
% GBM clients non- European/Pakeha	42%	52%	40%	52%
% GBM clients Maori	4%	4%	9%	6%
% GBM clients reporting non-recent testing (never or not in last 12 months)	29%	33%	64%	29%
% GBM clients reporting infrequent condom-use	33%	31%	47%	16%
Positivity rate (per 1000 tests)	5.4	3.3	5.0	8.1

Innovation and Significance:

Understanding demographic profile and risk factors of clients using different testing service types is useful in evaluating their effectiveness. These insights can support how NZAF apportion future testing resources and more importantly the ways that we can target testing communication in relation to each testing opportunity.

Disclosure of Interest Statement

New Zealand AIDS Foundation is a registered Charitable Trust funded through New Zealand government and private donations and granting bodies. No pharmaceutical grants were received in the development of this project.

Abstract